Literature DB >> 20554016

Metabolic profile of first and second generation antipsychotics among Chinese patients.

Edwin Lee1, Lai-Yin Chow, Chi-Ming Leung.   

Abstract

The metabolic profiles of Chinese patients treated with second-generation antipsychotic (SGA) medication and first-generation antipsychotic (FGA) medication were compared. The sample comprised 99 patients treated with SGA (risperidone, olanzapine and ziprasidone) and 99 with FGA (chlorpromazine, haloperidol and trifluoperazine) from the outpatient clinic of a teaching hospital in Hong Kong. The most frequent psychiatric diagnosis was schizophrenia, followed by affective disorder and other psychiatric diagnoses. Subjects were measured for body weight, body height, fasting lipid and glucose levels. SGA was associated with higher LDL-cholesterol level than FGA. Individual comparison of different antipsychotics showed that patients on olanzapine had the greatest increases in cholesterol and triglycerides among all antipsychotics. The finding suggested SGA, particularly olanzapine, were associated with more metabolic risk factors than first-generation antipsychotics.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20554016     DOI: 10.1016/j.psychres.2010.04.050

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

1.  Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.

Authors:  Srihari Gopal; Joris Berwaerts; Isaac Nuamah; Kasem Akhras; Danielle Coppola; Ella Daly; David Hough; Joseph Palumbo
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-08       Impact factor: 2.570

2.  Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine.

Authors:  Cüneyt Unsal; Yakup Albayrak; Neslihan Albayrak; Murat Kuloglu; Kenji Hashimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-11       Impact factor: 2.570

3.  The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Authors:  William Montgomery; Li Liu; Michael D Stensland; Hai Bo Xue; Tamas Treuer; Haya Ascher-Svanum
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-14

4.  Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.

Authors:  Subin Park; Ki Kyoung Yi; Min-Seon Kim; Jin Pyo Hong
Journal:  Behav Brain Funct       Date:  2013-07-19       Impact factor: 3.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.